States Move to Drop GLP-1 Weight Loss Drugs

Why Are States Reconsidering GLP-1 Coverage for Obesity?

GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound) have transformed obesity treatment, with clinical trials showing average weight reductions of roughly 15% to 20% of body weight. Demand among Medicaid enrollees has grown sharply since the FDA approved these medications for chronic weight management, and several states that initially extended coverage are now reassessing whether their budgets can sustain it.

Federal Medicaid law has historically excluded drugs used for weight loss from required coverage, leaving the decision to individual states. According to reporting by Stateline, states including North Carolina and others have already scaled back or dropped obesity coverage of GLP-1s, and additional states are now weighing similar moves as projections show the medications could consume a growing share of pharmacy spending if uptake continues at current rates.

What Does the Evidence Say About GLP-1 Drugs for Obesity?

The STEP trials of semaglutide and the SURMOUNT trials of tirzepatide established these agents as the most effective pharmacologic treatments for obesity to date, with benefits extending beyond weight to improvements in blood pressure, glycemic control, and lipid profiles. The SELECT trial, published in the New England Journal of Medicine, also demonstrated that semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

Despite this evidence, payers point out that benefits depend on continued use — discontinuation typically leads to weight regain — meaning Medicaid programs would face indefinite costs per enrolled patient. Health policy analysts have noted that without negotiated price reductions or rebates, broad coverage at current list prices may not be financially sustainable for state programs already managing tight pharmacy budgets.

What Are the Implications for Patients and Public Health?

More than 40% of US adults are estimated to have obesity, according to CDC data, with disproportionately high rates among Medicaid-eligible populations. Restricting GLP-1 coverage may force patients onto older, less effective therapies or out of treatment entirely, even though obesity is a recognized driver of cardiovascular disease, type 2 diabetes, and certain cancers.

Some states are exploring narrower coverage criteria — for example, limiting GLP-1 prescriptions to patients with higher BMI thresholds, established cardiovascular disease, or comorbid type 2 diabetes — as a middle path between full coverage and exclusion. The Centers for Medicare & Medicaid Services has also signaled interest in how these drugs are reimbursed, and ongoing federal price negotiation efforts under the Inflation Reduction Act may eventually affect what states pay.